"The fear is that this becomes a trend," said James Beck, the Chief Scientific Officer at the Parkinson’s Foundation. “Other pharmaceutical companies are also weighing this option and if the biggest of the bunch decides to exit the party, it might have a ripple effect on the others,” he told Newsweek.
Newsweek: After Trump Tax Break Pfizer Ends Funding For Alzheimer's, Parkinson's Research And Gives Billions To Investors
After Mindy McIlroy received her Parkinson’s diagnosis four years ago, she was afraid to tell her employer. Terranova, and her industry peers, responded with overwhelming support. Parkinson’s Foundation mentioned, as Mindy serves on our Board.
A PD diagnosis is associated with greater Medicare costs and out-of-pocket spending, according to a population-based Parkinson’s Foundation study. The Parkinson’s Foundation study is explained and John L. Lehr, CEO, and James Beck, PhD, the Foundation’s chief scientific officer, is quoted.
People with Parkinson’s generally experience a longer hospital stay than those entering the hospital for the same diagnosis without PD, and can develop more complications. This article cites Parkinson’s Outcomes Project data and promotes the Foundation’s Aware in Care kit as an “excellent resource for patients with PD who are going to the hospital.”
The most potent drug available for Parkinson's, levodopa, treats symptoms of the disease, but does not ease or increase its still-mysterious underlying causes, a new clinical trial has concluded. Dr. Michael S. Okun, Parkinson’s Foundation national medical director, is quoted.
Organizations and non-profits funded millions of dollars in neurogenerative disease research in 2018. The Parkinson’s Foundation is highlighted for its $6.2 million research grant investment.
Telemundo show Al Rojo Vivo interviews Adolfo Diaz, Parkinson’s Foundation Senior Director of Patient Services, about Foundation resources and Parkinson’s disease, along with Guido and Marina Hernandez who speak about how they utilize local exercise classes (Foundation community grant recipients) and live with Parkinson’s.
The U.S. Food and Drug Administration has approved a new treatment for intermittent treatment of “off” periods in people with Parkinson’s disease treated with carbidopa/levodopa.
Returning HPR guest writer John L. Lehr, Parkinson’s Foundation CEO, discusses the commitment and efforts of the Parkinson’s Foundation in advancing training of neurologists who specialize in PD.
With the goal of establishing a consensus on medical marijuana use by Parkinson’s patients — which a recent survey co-sponsored by the Parkinson’s Foundation put at 80 percent — the group will host its first conference focused on this compound and the disease.